Please login to the form below

Not currently logged in


This page shows the latest Proximagen news and features for those working in and with pharma, biotech and healthcare.

Artificial intelligence firm licenses Janssen candidates for development

Artificial intelligence firm licenses Janssen candidates for development

BenevolentAI was founded in 2013 as a spin-out of pharmaceutical company Proximagen.

Latest news

  • Roche drops superbug partnership with Polyphor Roche drops superbug partnership with Polyphor

    Roche drops superbug partnership with Polyphor. But adds inflammation research agreement with Proximagen. ... VAP-1 is a cell-adhesion molecule that may have a role to play in the treatment of inflammation, and Proximagen has taken its inhibitor into a

  • Pharma deals for June 2012 Pharma deals for June 2012

    Upsher-Smith took the acquisition route to replenish its pipeline, in this case by acquiring its long-term partner Proximagen. ... Proximagen's phase II compound PRX00933 has the same mechanism-of-action. Proximagen will receive an upfront payment of

  • High hopes

    Proximagen eyes AIM. Another university spin-out, Proximagen, is also planning to list on the stock market.

  • The waiting game

    Encouraging maiden interim results from Proximagen Neuroscience, a drug company specialising in neurodegenerative diseases, gave its depressed share price a useful lift.

  • Pharma stocks battle on

    funds. Meanwhile, Proximagen, a drug developer, made a good debut on AIM with its shares up 6p on the 148p offer price.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    its other companies Proximagen, an early-stage drug discovery and development company, and Pairnomix, a genetics research company.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...